dc.contributor.author | Armagan, Berkan | |
dc.contributor.author | Robinson, Susan | |
dc.contributor.author | Bazoberry, Adriana | |
dc.contributor.author | Grader-Beck, Thomas | |
dc.contributor.author | Baer, Alan | |
dc.date.accessioned | 2021-06-03T05:20:05Z | |
dc.date.available | 2021-06-03T05:20:05Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 0003-4967 | |
dc.identifier.uri | http://dx.doi.org/10.1136/annrheumdis-2019-eular.3387 | |
dc.identifier.uri | http://hdl.handle.net/11655/23981 | |
dc.language.iso | en | |
dc.relation.isversionof | 10.1136/annrheumdis-2019-eular.3387 | |
dc.rights | Attribution 4.0 United States | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Antibodies To Both Ro52 And Ro60 Define A Subset Of Sjogren'S Most Suitable For Clinical Trials Of Agents Targeting Lymphoproliferations | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Annals Of The Rheumatic Diseases | |
dc.contributor.department | İç Hastalıkları | |
dc.identifier.volume | 78 | |
dc.identifier.issue | 2 | |
dc.description.index | WoS | |